Paracetamol overdose and N-acetylcysteine

Paracetamol (acetaminophen) remains the most common cause of acute liver failure (ALF) in Australia and New Zealand. Toxicity is mechanistically predictable,an overflow of reactive metabolite production overwhelming cellular antioxidant defences,making it one of the most treatable poisonings if identified early. ICU involvement spans the spectrum from borderline ingestions requiring nomogram interpretation to fulminant hepatic failure demanding transplant assessment.

Hepatic Metabolism of Paracetamol

Normal Metabolic Pathways

At therapeutic doses, paracetamol is metabolised predominantly by:

NAPQI (N-acetyl-p-benzoquinone imine) is the toxic electrophilic metabolite. At therapeutic doses, hepatic glutathione (GSH) stores neutralise NAPQI immediately,$\text{GSH} + \text{NAPQI} \rightarrow \text{GS-NAPQI conjugate} \rightarrow \text{cysteine/mercapturic acid adducts}$.

Glutathione Depletion Mechanism

In overdose:

• Sulfation and glucuronidation become saturated at high substrate concentrations.
• A disproportionately larger fraction is shunted through CYP2E1 → NAPQI.
• NAPQI production overwhelms hepatic GSH stores (depleted to <30% of normal).
• Unscavenged NAPQI covalently binds hepatocellular proteins and mitochondrial membranes → lipid peroxidation, mitochondrial dysfunction, hepatocyte necrosis.
• Damage is centrilobular (zone 3),highest CYP2E1 expression, lowest oxygen tension.

Factors Increasing CYP2E1 Activity (Higher Risk)

• Chronic alcohol use (induces CYP2E1)
• Isoniazid, rifampicin, carbamazepine, phenytoin (enzyme inducers)
• Fasting/malnutrition (depletes GSH baseline)
• HIV/AIDS, eating disorders

Pitfall: Chronic alcoholism is often cited as greatly increasing risk, but the net effect is complex, induction of CYP2E1 increases NAPQI production, but alcoholic liver disease may also reduce GSH synthesis. These patients should be treated at lower thresholds.

Dose Thresholds and Clinical Risk Stratification

Acute Single Ingestion

• Potentially toxic threshold: $\geq 150\ \text{mg/kg}$ or $\geq 10\ \text{g}$ (whichever is lower) in a single acute ingestion.
• Below this threshold and with a low 4-hour serum level, treatment is generally not required.
• Serum paracetamol level at 4 hours post-ingestion is the definitive risk stratification tool.

Modified-Release (Extended-Release) Formulations

Modified-release paracetamol (e.g. Panadol Osteo 665 mg tablets) has biphasic absorption, delayed Tmax, and higher risk of underestimating peak levels:

• A single 4-hour level may be falsely reassuring.
• Australian Therapeutic Guidelines/Toxicology (ATIC/clinical toxicology consensus): take levels at 4 h and 8 h post-ingestion; treat if either exceeds the treatment line, or commence empirical NAC if ingestion >10 g or >150 mg/kg regardless of 4-hour level.
• The Rumack-Matthew nomogram is not validated for modified-release preparations.

Staggered Ingestion

• Multiple doses over >1 hour,the nomogram cannot be applied (no defined time zero).
• Risk assess on: total dose ingested, patient's background hepatic risk factors, current LFTs, INR.
• General consensus: if total staggered dose exceeds $150\ \text{mg/kg}$ or $10\ \text{g}$, treat empirically with NAC without waiting for a nomogram interpretation.

Pitfall: Clinicians occasionally attempt nomogram interpretation after staggered overdose by estimating "time of peak dose",this is unreliable and not recommended by Australian Poisons Information Centres (13 11 26).

Rumack-Matthew Nomogram

Structure and ANZ-Specific Treatment Line

The nomogram plots serum paracetamol concentration (mg/L) against time post-ingestion (hours). In Australia and New Zealand, the treatment threshold is:

$$\text{Treatment line: } 150\ \text{mg/L at 4 hours}$$

This corresponds to the "150-line" (lower than the original North American 200-line), providing a safety margin. The line decreases log-linearly thereafter with a t½ slope assumed at ~4 h.

• If level above the treatment line → start NAC immediately.
• If level below the treatment line AND timing is certain AND formulation is immediate-release → NAC not required (observe, recheck if symptomatic).

Nomogram Limitations, When NOT to Use

Key rule: If timing is uncertain, modified-release is involved, or the patient is late to present, treat empirically and do not rely on the nomogram.

N-Acetylcysteine (NAC), Mechanism of Action

NAC (Acetadote® IV formulation, Sigma/Alphapharm in Australia) works through multiple complementary mechanisms:

1. Glutathione Replenishment

NAC is a cysteine prodrug. Intracellularly: $$\text{NAC} \rightarrow \text{cysteine} \rightarrow \text{glutathione (via } \gamma\text{-glutamylcysteine synthetase)}$$ Replenishing hepatic GSH allows continued NAPQI scavenging even after depletion.

2. Direct NAPQI Scavenging

At high concentrations (especially with IV loading), NAC can directly conjugate NAPQI as a nucleophile,bypassing the need for GSH regeneration.

3. Antioxidant and Microcirculatory Effects

• Reduces oxidative stress via free radical scavenging (thiol groups).
• Improves hepatic and renal microcirculation (vasodilatory effect, possibly via NO augmentation).
• Reduces neutrophil infiltration in early hepatic injury.
• Benefits seen even in established hepatotoxicity, where these non-GSH mechanisms dominate.

4. Mitochondrial Protection

NAC supports mitochondrial bioenergetics, which are targeted by NAPQI-adduct formation,relevant in late presentations.

ANZ NAC Dosing Regimen

Current ANZ Two-Bag Regimen (Recommended)

The two-bag regimen replaces the older three-bag regimen in most Australian centres, endorsed by Australian clinical toxicology consensus and reflected in Therapeutic Guidelines:

Dilute in 5% dextrose (500 mL for adults). Weight-cap at 110 kg for dose calculation in obesity.

Pitfall: The two-bag regimen front-loads NAC more aggressively than the old three-bag regimen (see below), which is intentional,higher early levels more effectively scavenge NAPQI during peak toxicity. However, this also concentrates the anaphylactoid risk into the first bag.

Older Three-Bag Regimen (Historical Reference)

Still encountered in older protocols and some references. Total dose and duration are similar; the loading rate differs.

When to Extend or Stop NAC

Extending Beyond Standard 21-Hour Course

Continue NAC (run Bag 2 repeatedly or at double dose per toxicology advice) if any of:

• ALT/AST rising at end of standard course
• INR ≥2.0 (or rising)
• Any degree of hepatic encephalopathy
• Paracetamol level still detectable (ongoing absorption in modified-release)
• Symptomatic hepatotoxicity (RUQ pain, jaundice, vomiting)

Stopping NAC

NAC can be safely ceased when all of:

• ALT trending downward (or normal)
• INR <2.0 and not rising
• No encephalopathy
• Patient clinically well, tolerating oral intake
• No detectable paracetamol level if modified-release was involved

Adverse Reactions to IV NAC

Anaphylactoid Reactions (Most Common)

• Mechanism: non-IgE-mediated, direct histamine release from mast cells, dose and rate dependent.
• Incidence: ~15% with old three-bag regimen (loading dose rate); lower with two-bag regimen modifications.
• Typically occurs in the first 15-30 minutes of infusion.
• Features: flushing, urticaria, pruritus, nausea/vomiting, bronchospasm; hypotension less common.
• Severity: usually mild-moderate (WHO grade 1-2).

True Anaphylaxis vs Anaphylactoid

• True IgE-mediated anaphylaxis to NAC is rare but documented.
• Skin prick testing unreliable acutely.
• If severe reaction: weigh risk-benefit, oral NAC (600 mg 4-hourly) is an alternative if IV absolutely not tolerated, though less effective in severe overdose.

Pitfall: Withholding NAC entirely after an anaphylactoid reaction is a significant management error. Slow re-challenge after appropriate treatment of the reaction is almost always feasible and essential.

Late Presentation (>8 Hours Post-Ingestion)

• Efficacy of NAC declines with time but never zero,benefit persists even at 24-36 h.
• At >8 h from ingestion, do not await blood results before starting NAC, empirically start NAC, then continue or stop based on level and ALT.
• At >24 h, nomogram is unreliable; base decisions on:
• Detectable paracetamol level
• Elevated ALT/AST
• Abnormal INR
• Clinical features of hepatotoxicity

Markers of Hepatotoxicity and Monitoring

Laboratory Monitoring

Clinical Staging of Toxicity

King's College Hospital (KCH) Criteria, Liver Transplant Assessment

Used to identify patients with paracetamol-induced ALF unlikely to survive without transplantation. Assess when hepatic failure is established (typically Phase 3).

KCH Criteria for Paracetamol-Induced ALF

$$\text{Arterial pH} < 7.30 \text{ (after resuscitation and >24h post-ingestion)}$$

OR all three of the "triad":

$$\text{INR} > 6.5 \quad \text{AND} \quad \text{Creatinine} > 300\ \mu\text{mol/L} \quad \text{AND} \quad \text{Encephalopathy grade III or IV}$$

Pitfall: pH <7.30 alone (after adequate volume resuscitation) is sufficient to trigger transplant referral,do not wait for the full triad to develop. Early contact with a liver transplant centre is essential.

Additional Poor Prognostic Markers (Not KCH, but Clinically Relevant)

• Lactate >3.5 mmol/L at 4 h OR >3.0 mmol/L at 12 h (post-resuscitation)
• Phosphate >1.2 mmol/L at 48-96 h (different from regeneration pattern)
• Factor V <10% or factor V:VIII ratio <30 (European criteria)
• MELD score >30
• Age >40, rapid encephalopathy progression

Role of Haemodialysis / Extracorporeal Elimination

Paracetamol is water-soluble, low molecular weight (151 Da), minimally protein-bound,highly dialysable.

Indications for Haemodialysis (Massive Ingestion)

Consider haemodialysis when:

• Serum paracetamol >900 mg/L (or >600 mg/L in some centres) with:
• Metabolic acidosis (pH <7.30)
• Coma
• Cardiovascular instability
• Very large ingestions where gut decontamination is insufficient
• Concurrent acute kidney injury requiring dialysis regardless

Practical Considerations

• Haemodialysis removes NAC as well,increase NAC infusion rate by 30-50% during dialysis (or administer supplemental NAC directly into the dialysis circuit).
• Haemofiltration (CVVHF) is less efficient for paracetamol clearance than intermittent haemodialysis.
• Contact Poisons Information (13 11 26) or clinical toxicology service for specific guidance in massive ingestions.

Key Numbers Reference

ICU Relevance

Monitoring in ICU

• Hourly neurological observations once encephalopathy develops.
• Arterial line for serial ABGs, lactate, and pH monitoring (KCH pH criteria).
• 4-hourly glucose in established ALF (hypoglycaemia is life-threatening).
• Continuous renal replacement therapy (CRRT) for AKI + ALF, but note reduced NAC clearance vs IHD.
• Daily INR, ALT, creatinine, phosphate, ammonia until clearly improving.

Escalation Triggers

• pH <7.30 post-resuscitation → immediate liver transplant referral (do not wait for full triad).
• Rising INR >4 + encephalopathy → high-care monitoring, FFP controversial (masks synthetic function assessment, avoid unless active bleeding or procedural requirement).
• Refractory hypoglycaemia → 50% dextrose boluses + 10% dextrose infusion, nasogastric feeds if encephalopathy permits.
• Coagulopathy + renal failure: liaise with haematology; recombinant FVIIa occasionally used as bridge to transplant but thrombotic risk is real.

Common ICU Scenarios and Pitfalls

Pitfall 1: Stopping NAC at 21 h because "the course is finished" without checking ALT trend,this is dangerous in late-presenting or modified-release ingestions where hepatotoxicity may be peaking.

Pitfall 2: Dismissing NAC anaphylactoid reaction as contraindication. Slow re-challenge after antihistamine treatment is almost universally successful and NAC must be restarted.

Pitfall 3: Waiting for the full KCH triad before contacting a transplant service. pH <7.30 alone warrants urgent referral; liver transplant assessment is time-sensitive.

Pitfall 4: Not increasing NAC dose during intermittent haemodialysis,paracetamol and NAC are both dialysed, requiring supplementation.

Pitfall 5: Using the nomogram for staggered ingestion or modified-release paracetamol. Treat empirically; don't attempt to "fit" a level to an invalid nomogram.

Specific Modified-Release ICU Scenario

Patients presenting after Panadol Osteo overdose often have early reassuring 4-hour levels (<150 mg/L), only for levels to peak at 8-12 h above the treatment line. Always check the 8-hour level; empirically treat if >10 g or >150 mg/kg ingested regardless of early level.

ALF Management Framework

When KCH criteria are met or approached:

1. Contact liver transplant unit immediately (AGPT or state-based transplant service).
2. List for transplant early, delisting if patient recovers is straightforward; late listing is not.
3. Manage ICP if grade III/IV encephalopathy: 30° head elevation, hypertonic saline target Na 145-155, consider ICP monitoring in select centres.
4. Avoid nephrotoxins; renal replacement early for acidosis, hyperammonaemia, volume.
5. N-acetylcysteine continues throughout, evidence of benefit even in non-paracetamol ALF (ALFSG trial, Lee et al. Gastroenterology 2009).